An investigational PCSK9 inhibitor with a different mechanism from existing drugs in this class has been shown to safely and effectively lower cholesterol levels.

Researchers at the VIB-UGent Center for Medical Biotechnology have discovered a promising strategy to improve treatment ...

The highly selective partial agonist at D1 and D5 receptors significantly improves motor function in patients recently ...

Initiation by Merck of a Phase 2 trial in Alzheimer’s disease with partnered α7 nicotinic acetylcholine receptor PAM MK-1167 highlights company’s ...

What are the most concerning consequences of the drug and other weight-loss medicines? - Gastrointestinal and cardiovascular complications are among the most serious side effects ...

People taking GLP-1 drugs can decrease fat mass while minimizing muscle loss with a few key strategies that include proper ...

Pfizer said it will stop development of an oral weight-loss pill after a participant taking the drug in a clinical trial ...

UF scientists have developed a compound that safely activates delta opioid receptors, offering pain relief without ...

Dr. Laura Finn brings new treatment options to Louisiana using genetically altered cells to treat blood cancer patients. Here ...

About half of Americans "strongly" or "somewhat" favor having Medicare and Medicaid cover weight-loss drugs for people who ...

If they can identify a drug that is already widely used and helps lower the risk of dementia ... similarly not involved in ...

Transferrin receptor (TfR)-mediated transcytosis is a receptor-mediated mechanism for drug delivery to the brain or other tissues, where, after the antibody binds to transferrin, the therapeutic agent ...